About US
Contact us
-
BioPharma India Convention 2010BioPharma India Convention 2010 is uniquely positioned as the only strategic event in India where global and Indian pharmaceutical companies, biotechs, CMOs, CROs, academic institutions and many other2010/4/9
-
Cleanroom infrastructure approaches completion at Vetter’s new Chicago facilityVetter, a leading provider of aseptic pre-filled drug-delivery systems, announced that cleanroom infrastructure will be completed by early May at its new Chicago facility - an expansion of Vetter Deve2010/4/9
-
Dow Electronic Materials Presents Innovative Materials for Printed Circuit Boards at IPC/APEX ExpoUnique technology delivers reliability, consistency and reduced cost for Printed Circuit Boards MARLBOROUGH, Mass.--(BUSINESS WIRE)--Dow Electronic Materials will present its innovative materials fo2010/4/8
-
BASF raises prices for morpholine globallyEffective immediately or as existing contracts allow, BASF is raising its morpholine sales prices globally by 150 Euros per metric ton or the equivalent amount in local currency. Morpholine is a va2010/4/8
-
Evonik announces price increaseEffective April 1, 2010, or as contract terms allow, Evonik Industries’ Household Care Business Line will increase the prices for all products marketed in Europe in the range of 10 %. These price incr2010/4/8
-
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 920100407(3).rar source: web of FDA2010/4/7
-
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 720100407(2).rar source:web of FDA2010/4/7
-
Guidance for Industry Q3C — Tables and List20100407(1).rar2010/4/7
-
EyeGate Pharma Completes Phase II Study of EGP-437 in Patients With Anterior UveitisEyeGate Pharma, a privately held venture-backed pharmaceutical company developing a non-invasive ocular drug delivery platform and ocular therapeutics, recently announced the completion of a P2010/4/6
-
Synairgen Initiates Phase II Trial With Inhaled Interferon Beta in Asthmatic SubjectsSynairgen plc, the respiratory drug discovery and development company with a particular focus on viral defense in asthma and chronic obstructive pulmonary disease (COPD), recently announced th2010/4/6